Alnajashi H. Rituximab as an off Label, High Efficacy Therapy in The Treatment of Multiple Sclerosis and Related Central Nervous System Demyelinating Diseases: Single Centre Experience and Literature Review. J. Contemp. Med. Sci. [Internet]. 2025 Jun. 26 [cited 2026 Oct. 23];11(3). Available from: https://www.jocms.org/index.php/jcms/article/view/1892